

July 9<sup>th</sup> 2018

Dear Doctor:

The safety of our patients is and will remain our top priority. We are aware of the decision to recall in several countries batches of Valsartan and Valsartan HCT film-coated tablets that do not meet with international quality standards. Quality assessments confirmed impurities in some batches of these products manufactured by an external supplier.

We want to emphasize that the active ingredient detected with the impurity is not used in the manufacturing process of **Diovan®**, **CoDiovan®**, **Exforge®**, **Exforge HCT®** and **Vymada®**, so we can confirm that none of these batches have been imported and/or distributed in the countries of this region.

At Novartis, we are committed to ensuring that our treatments are safe and comply with the highest quality standards.

We share with you our commitment to patients, so if you like to expand any information regarding this subject our medical staff will be pleased to help you through the following email: [medical.info\\_service@novartis.com](mailto:medical.info_service@novartis.com)

Sincerely,

Alexandre Miotto  
CVM Franchise Director for  
Novartis Central America & Caribbean

Ana Lucía Guzmán  
Chief Scientific Officer for Novartis  
Central America & Caribbean